{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:47:17Z","timestamp":1792820837088,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7893\/A28990"],"award-info":[{"award-number":["C7893\/A28990"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTUQQR-Dec22\/100002"],"award-info":[{"award-number":["CTUQQR-Dec22\/100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["UKRI1417"],"award-info":[{"award-number":["UKRI1417"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203322"],"award-info":[{"award-number":["NIHR203322"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijrobp.2026.06.3067","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:37:30Z","timestamp":1785386250000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Project Optimus for Radiation Therapy\u2013Drug Combinations: Moving Beyond the Maximum Tolerated Dose"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-0387","authenticated-orcid":false,"given":"Alastair","family":"Greystoke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie A.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus T.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard G.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crispin","family":"Hiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McAlister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Oughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl T.","family":"Butterworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"Walls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0001","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ncponc0744","article-title":"Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions","volume":"4","author":"Bentzen","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0002","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/psp4.13079","article-title":"Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development","volume":"13","author":"Gao","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","article-title":"Oncology phase I trial design and conduct: Time for a change - MDICT guidelines 2022","volume":"34","author":"Araujo","year":"2023","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0004","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2010.02.009","article-title":"A systematic methodology review of phase I radiation dose escalation trials","volume":"95","author":"Pijls-Johannesma","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0005","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0006","doi-asserted-by":"crossref","first-page":"S1395","DOI":"10.1016\/S0167-8140(25)01767-0","article-title":"3513 ATM inhibition with AZD1390 and conventional radiotherapy in non-small cell lung cancer: Interim report from the CONCORDE phase Ib trial (NCT04550104)","volume":"206","author":"Walls","year":"2025","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0007","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100301","article-title":"Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020","volume":"6","author":"Maliepaard","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0009","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ijrobp.2021.07.1709","article-title":"Overview and lessons from the preclinical chemoradiotherapy testing consortium","volume":"111","author":"Buchsbaum","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0010","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2011.240","article-title":"Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers","volume":"105","author":"Harrington","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0012","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S1470-2045(24)00264-X","volume":"25","author":"Zumsteg","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0013","first-page":"61","article-title":"CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer","volume":"25","author":"Walls","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0014","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1158\/1078-0432.CCR-21-4087","article-title":"A road map for designing phase I clinical trials of radiotherapy-novel agent combinations","volume":"28","author":"Brown","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0016","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ijrobp.2026.01.003","article-title":"Integration of immune checkpoint blockade with radiation in lung cancer: Lessons from recent trials","volume":"124","author":"Adib","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0017","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: Results of the phase I OPARATIC trial","volume":"22","author":"Hanna","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0018","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40900-024-00599-7","article-title":"Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs","volume":"10","author":"Alger","year":"2024","journal-title":"Res Involv Engagem"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102838","article-title":"Advancing patient-centric care: Integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable","volume":"76","author":"Yap","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO-25-01625","article-title":"International consensus-driven recommendations for patient-reported outcome research objectives in early phase dose-finding oncology trials: OPTIMISE-ROR","volume":"44","author":"Alger","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0021","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(26)00018-5","article-title":"A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR)","volume":"27","author":"Alger","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0022","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12874-024-02398-w","article-title":"Determining doses for backfill cohorts based on patient-reported outcome","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0023","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jtho.2024.04.006","article-title":"Treatment response biomarkers: Working toward personalized radiotherapy for lung cancer","volume":"19","author":"Horne","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0024","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","article-title":"A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary","volume":"15","author":"Conway","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110935","article-title":"A systematic review and meta-analysis of the utility of quantitative, imaging-based approaches to predict radiation-induced toxicity in lung cancer patients","volume":"208","author":"Tong","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0026","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0027","unstructured":"U.S. Department of Health and Human Services, Use of circulating tumor DNA for curative-intent solid tumor drug development guidance for industry, F.a.D. Administration, Editor, 2024, Office of Communications, Division of Drug Information. Center for Drug Evaluation and Research. Available at https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumour-dexoyribonucleic-acid-early-stage-solid-tumour-drug-development-guidance. Accessed July 22, 2026"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0028","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s00330-021-08277-y","article-title":"CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy","volume":"32","author":"Yang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0029","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s10278-020-00385-3","article-title":"Radiomic analysis of CT predicts tumor response in human lung cancer with radiotherapy","volume":"33","author":"Yan","year":"2020","journal-title":"J Digit Imaging"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0030","article-title":"Imaging biomarkers to predict and evaluate the effectiveness of immunotherapy in advanced non-small-cell lung cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0031","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.3390\/cancers17193121","article-title":"Radiomics-driven tumor prognosis prediction across imaging modalities: Advances in sampling, feature selection, and multi-omics integration","volume":"17","author":"Huang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0032","doi-asserted-by":"crossref","first-page":"pkab046","DOI":"10.1093\/jncics\/pkab046","article-title":"Moving forward in the next decade: Radiation oncology sciences for patient-centered cancer care","volume":"5","author":"Coleman","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0033","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2014.05.044","article-title":"Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned","volume":"90","author":"Faivre-Finn","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0034","article-title":"Implementation of the time-to-event continuous reassessment method design in a phase I platform trial testing novel radiotherapy-drug combinations-CONCORDE","volume":"6","author":"Walker","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0035","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0036","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-18-0246","article-title":"Time-to-event Bayesian optimal interval design to accelerate phase I trials","volume":"24","author":"Yuan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.06.3067_bib0037","first-page":"1375","article-title":"Randomized phase II clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626039210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626039210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:50:53Z","timestamp":1788551453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626039210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"alternative-id":["S0360301626039210"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.06.3067","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Project Optimus for Radiation Therapy\u2013Drug Combinations: Moving Beyond the Maximum Tolerated Dose","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.06.3067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}